金城医药(300233.SZ)：米拉贝隆取得化学原料药上市申请批准

Core Viewpoint - Jincheng Pharmaceutical (300233.SZ) announced that its wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the approval notice for the marketing application of the chemical raw material drug Mirabegron from the National Medical Products Administration [1] Group 1 - The chemical raw material drug approved is named Mirabegron, which is a selective β-3 adrenergic receptor agonist [1] - Mirabegron is primarily used for the treatment of overactive bladder (OAB), including symptoms such as urinary incontinence, urgency, and frequency [1]